Healthcare Wire Hong Kong: Press Releases

Bicycle Toxin Conjugates Clinical Trials FDA Approval Proprietary Technology Cancer Drugs Report 2025

Delhi, Aug. 29, 2025 (GLOBE NEWSWIRE) -- Global Bicycle Toxin Conjugates Clinical Trials, Proprietary Platforms …

RNA Polymerase I POL 1 Clinical Trials Companies FDA Approval Development Trends Report 2025

Delhi, Aug. 29, 2025 (GLOBE NEWSWIRE) -- Global RNA Polymerase I Clinical Trials, Development Trends By Indications, Target Approaches …

Tetraspecific Antibodies Clinical Trials FDA Approval Development Technologies Platforms Market Opportunity Companies Report 2025

Delhi, Aug. 29, 2025 (GLOBE NEWSWIRE) -- Global Tetraspecific Antibodies Clinical Trials, Proprietary Technologies, Therapeutic Approaches …

Bispecific Antibody Drug Conjugates ADC Clinical Trials FDA Approval Companies Commercial Launch Report 2025

Delhi, Aug. 29, 2025 (GLOBE NEWSWIRE) -- Global Bispecific Antibody Drug Conjugates Clinical Trials, Development Platforms, Competitive Landscape and Market Opportunity Insight 2025 Report Findings and Highlights: First Bispecific Antibody Drug Conjugate …

Controlled Release Drug Delivery Market Size FDA Approved Drugs Clinical Trials Companies Report 2030

Delhi, Aug. 29, 2025 (GLOBE NEWSWIRE) -- Global Controlled Release Drug Delivery Market, Drug Dosage, Price, Sales and Clinical Trials Insight 2030 Report Finding and Highlights: Research Methodology Followed Global and Regional Market Overview Global …

OSE Immunotherapeutics Reaffirms its Strategic Priorities and Publishes Shareholder Q&A to Restore Information Ahead of AGM

OSE Immunotherapeutics Reaffirms its Strategic Priorities and Publishes Shareholder Q&A to Restore Information Ahead of AGM Nantes, August 29, 2025, 8:00 a.m. CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) today published a comprehensive …

OSE Immunotherapeutics Réaffirme ses Priorités Stratégiques et Publie un Document Questions-Réponses Destiné aux Actionnaires pour Rétablir l’Information Avant l’Assemblée Générale

OSE Immunotherapeutics Réaffirme ses Priorités Stratégiques et Publie un Document Questions-Réponses Destiné aux Actionnaires pour Rétablir l’Information Avant l’Assemblée Générale NANTES, France - 29 août 2025, 8h00 CET – OSE Immunotherapeutics SA (ISIN: …

Santhera schliesst Vereinbarung mit Ikris Pharma Network über den Vertrieb von AGAMREE® (Vamorolon) in Indien

Pratteln, Schweiz, 29. August 2025 – Santhera Pharmaceuticals (SIX: SANN) gibt die Unterzeichnung einer exklusiven Vereinbarung mit Ikris Pharma Network (Ikris) über den Vertrieb von AGAMREE® (Vamorolon) in Indien zur Behandlung von Duchenne- …

Santhera Enters into Agreement with Ikris Pharma Network for the Distribution of AGAMREE® (Vamorolone) in India

Pratteln, Switzerland, 29 August, 2025 – Santhera Pharmaceuticals (SIX: SANN) announces the signing of an exclusive agreement with Ikris Pharma Network (Ikris) to manage the distribution of AGAMREE® (vamorolone) in India, for the treatment of Duchenne …

Banner Year for Mesoblast With First FDA Product Approval and Successful Commercial Launch of Ryoncil®

NEW YORK, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines for inflammatory diseases, today provided financial results and an operational update for the period ended June 30, 2025. …